These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12022712)

  • 41. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life.
    Djavan B
    Urology; 2003 Sep; 62(3 Suppl 1):6-14. PubMed ID: 12957195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
    Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
    Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The concept of uroselectivity.
    Andersson KE
    Eur Urol; 1998; 33 Suppl 2():7-11. PubMed ID: 9556190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.
    Mirone V; Sessa A; Giuliano F; Berges R; Kirby M; Moncada I
    Int J Clin Pract; 2011 Sep; 65(9):1005-13. PubMed ID: 21718399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study.
    Masumori N; Tsukamoto T; Horita H; Sunaoshi K; Tanaka Y; Takeyama K; Sato E; Miyao N
    Int J Urol; 2013 Apr; 20(4):421-8. PubMed ID: 22989348
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
    Roehrborn CG; Schwinn DA
    J Urol; 2004 Mar; 171(3):1029-35. PubMed ID: 14767264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Müderrisoglu AE; de la Rosette JJMCH; Michel MC
    Expert Opin Drug Saf; 2023; 22(12):1213-1224. PubMed ID: 38064204
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Momose H; Hosokawa Y; Kishino T; Ono T; Oyama N
    Drugs Today (Barc); 2007 Feb; 43 Suppl A():1-10. PubMed ID: 17401467
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
    O'Leary MP
    Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alfuzosin: a clinically uroselective alpha1-blocker.
    Höfner K; Jonas U
    World J Urol; 2002 Apr; 19(6):405-12. PubMed ID: 12022709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists.
    Milani S; Djavan B
    BJU Int; 2005 Jun; 95 Suppl 4():29-36. PubMed ID: 15871733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?
    Puppo P
    Eur Urol; 2001 Jan; 39 Suppl 2():38-41. PubMed ID: 11223696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Drug therapy for benign prostatic syndrome (BPS)].
    Berges R
    Aktuelle Urol; 2006 Sep; 37(5):351-62. PubMed ID: 17004180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.